More importantly, Abx-treated mice exhibited a similar alleviation of NAFLD as Tcrd−/− mice fed with HFD/HFHCD, as indicated by the reduced steatohepatitis (Fig. 9a,b), the reduced ALT level (Fig. 9c), the elevated body weight (Fig. 9d) and the catabatic glucose dysmetabolism (Fig. 9e). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.